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Abstract 
Q fever is a worldwide zoonosis that may cause reproductive disorders such as abortion, endometritis or infertility in livestock. 
The implementation of a vaccination with a phase I vaccine is the nowadays the most relevant way to control the spread of the 
infection within herds. Annual boosters are recommended for ruminants by the manufacturer whereas in humans, to prevent side 
effects, no booster must be done before 5 years and the lack of humoral and cellular immunity has to be confirmed before any 
additional vaccination. The aim of this study was to investigate, in dairy cattle, the interest of such annual booster by assessing 
the level of different immune markers among 142 animals (from infected and uninfected herds) vaccinated either 2 year (i.e. 2 
times) or 1 year before with an efficient commercial phase I Q fever vaccine. One year after vaccination, more than 80 % of the 
vaccinated cows had still immune markers, whereas 68 % of the heifers from uninfected herd did not. These data suggested that 
an annual booster would not be necessary for all vaccinated animals within a herd. In order to detect the immune animals and 
then to optimize the number of animals needing a boost, the skin test method, performed at least 3 days before the vaccination 
could be used. 
© 2009 Elsevier B.V. 
Keywords: Coxiella burnetti; vaccine; dairy cattle; humoral immunity; cellular immunity. 
1. Introduction 
Coxiella burnetii, the causative agent of Q fever, a zoonosis of worldwide distribution, infects various animal 
species. C burnetii is associated with pneumonia and reproductive disorders in livestock including abortion, 
stillbirth, delivery of weak and unviable newborns, endometritis and infertility [1]. Ruminants are considered as the 
most common reservoir for human infections as infected ruminants shed high load of C burnetii in placenta and 
parturition products but also in feces and urine, which are the source of environmental contaminations causing 
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human diseases. Coxiella burnetii may also be shed via milk but oral transmission of the bacteria is considered as 
less common as well as the possibility of vertical and sexual transmission [1]. Human Q fever usually manifests as a 
flu-like, self-limiting acute illness although some infections develop into a severe and sometimes fatal chronic 
disease [2]. Within dairy herd, the implementation of vaccination is nowadays the most effective control measure to 
prevent and control C. burnetii shedding. C burnetii undergoes a phase variation in which smooth-LPS virulent 
phase I converts to rough-LPS avirulent phase II upon serial passage in non immunocompetent cells. Only phase I 
vaccines are effective in reducing both abortion and shedding of the bacteria in milk, vaginal mucus and feces of 
ruminants [3,4]. 
In veterinary medicine, annual boosters are often stipulated for inactivated vaccines, but their grounds are rarely 
studied. For Q fever, annual boosters are recommended for ruminants by the manufacturer whereas in humans, to 
prevent side effects, no booster must be done before 5 years and the lack of humoral and cellular immunity has to be 
confirmed using antibody level determination and skin test before any additional vaccination [5]. Therefore, the aim 
of this study was to investigate, in dairy cattle, the level of different immune markers among 142 animals vaccinated 
2 year (i.e. 2 times) or 1 year (i.e. one time) before with a commercial phase I Q fever vaccine (Coxevac® CEVA 
Santé Animale Libourne France) in order to confirm or not the interest of an annual booster with such a vaccine. 
2. Materials and Methods 
To reach this goal, forty-four animals (22 heifers and 22 cows) from an uninfected herd and 98 animals (42 
heifers and 56 cows) from 5 infected herds with abortions due to Q fever (confirmed by positive PCR on placenta) 
were included in the study. The uninfected herd showed a within herd seroprevalence of 0%. As the immune 
response could be influenced by naturally acquired immunity, only cows tested both negative in ELISA and in PCR 
(on concomitant samplings of vaginal mucus and milk) before vaccination, and still PCR negative-tested one year 
after last injection were included in the study [4]. Among these 142 animals, 36 animals from infected herds have 
been vaccinated the 2 preceding years, i.e. have received a primo-vaccination and a annual boost (VAC 2) and 106 
have been vaccinated for the first time the preceding year (VAC 1). 
To investigate the cellular immune response, we used a skin test (ST) method consisting in an intradermal 
inoculation of 0.1 mL of the vaccine diluted 1/3 in the neck followed by a reading 72 to 96 h after. The ST was 
considered as positive when a nodular area > 1cm was observed. 
To investigate the humoral immune response the level of antibody in serum samples was determined by ELISA 
using Ruminant serum Q Fever LSI kit (LSI, Lissieu, France), the day of the skin test (day 0) and 10 days after. The 
results were expressed in optical density Sample/Positive control (S/P) ratio. A serum was considered positive when 
S/P ratio > 40. To assess the booster effect of the skin test an Index S was calculated from the comparison of the 
antibody titer on day 0 (ATD0) and the antibody titer on day 10 (ATD10). S was estimated as follows: (ATD10-
ATD0)/ATD0. When both ATD0 and ATD10 were <40 then S = 0; and when ATD0=0 and ATD10 > 40, then S = 
2. We considered than the skin test induced a booster effect if we observed an index S > 0.3 according to the data of 
unvaccinated control animals in uninfected herd (data not shown). 
To investigate the putative differences according to the vaccination scheme (VAC1 vs VAC2), the lactation stage 
of animals (cows vs heifers) or the status of the herd (infected vs uninfected), we compared distribution among 
different groups using χ2 test for qualitative values and Kruskall-Wallis test for the quantitative values. In a first 
step, we compared the number of seropositive animals at day 0 according to their vaccination scheme and their 
status at first vaccination. In a second step, the distribution of skin-tested positive or negative animals were 
compared according to their vaccination scheme and their status at first vaccination. Lastly, the putative booster 
effect was investigated when comparing the index values according to the vaccination scheme. 
3. Results and discussion 
One year after the last injection of vaccine, 125 out of 142 animals were still ELISA positive. The number of 
positive animals (heifers and cows together) and the  mean antibody titer were significantly higher (p < 0.006 and p 
< 0.02 respectively) in the animals vaccinated the 2 preceding years (i.e. 2 times, VAC2) than in the animals 
vaccinated for the first time the year before (i.e. 1 time, VAC1) (mean antibody titer = 109 + 66 and 75 + 84, 
Rodolakis A et al. / Procedia in Vaccinology 1 (2009) 85–88 87
respectively). However, among the subsample of cows, the number of positive animals was not significantly 
different between VAC1 and VAC2 groups. The difference observed in the number of positive animals was due to 
the age at the time of vaccination, more than to the number of vaccinations. Indeed, while 16 heifers out of 21 
vaccinated before 14 months of age were still seronegative one year after vaccination, only 4 out of 16 heifers 
vaccinated after 18 months of age were still seronegative after vaccination. Among heifers first vaccinated after 18 
months of age, the proportion of seropositive animals one year after the last injection of vaccine was not different 
according to the number of vaccination (VAC1 or VAC2) (Table 1).  
Table 1 Distribution of seropositive and seronegative animals on day 0 according to their lactation number (heifers vs cows), 
their age at first vaccination, their vaccination scheme (VAC1 vs VAC2) and their belonging herd. 
Infected herds Uninfected herd 
Heifers  age when 1st vaccinated Cows 
<14 months >18 months 
ELISA on  
the day of 
skin test VAC1a VAC1 VAC2 VAC1 VAC2 
Heifers Cows 
Positiveb 5 (24%) 12 (75%) 4 (80%) 18 (72%) 26 (84%) 3 (14%) 15 (70) 
Negative 16 (76%) 4 (25%) 1 (20%) 7 (28%) 5 (16%) 19 (86%) 7 (30) 
Total 21 16 5 25 31 22 22 
a) VAC1 = animals vaccinated for the first time 1 year before, VAC2 = animals vaccinated the 2 preceding years (i.e. 2 times) 
b) Positive = optical density Sample/Positive control (S/P ratio) > 40  
Regarding cellular immunity, 91 animals out of 142 (64%) were considered as skin-tested positive (Figure 1) 
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Figure 1. Distribution of skin-tested positive and negative animals according to their herd, their lactation status (cows vs heifers) 
and their vaccination scheme (IH: infected herd)
As for the humoral response, there were significantly less skin-tested positive animals among heifers than in 
cows (p <0.001) regardless the type of comparison (Fig 1), whether all the cows were compared to all the heifers, 
(p <0.01) or only the cows and the heifers vaccinated for the first time the preceding year (VAC1 group), within 
infected (p <0.05) or in the uninfected herd (p <0.05). 
The number of vaccination (VAC1 or VAC2) did not significantly increase the number of skin-tested positive 
cows (Figure 1). However, the number of skin tested positive animals was significantly higher in the infected herds 
(IH) than in the uninfected one (UIH) regardless the type of comparison: whether all the animals were compared 
(p <0.001) or only the animals vaccinated one year before (VAC1) (p <0.001), or when the cows or the heifers 
vaccinated for the first time the preceding year in the infected herds were respectively compared to the cows or the 
heifers vaccinated for the first time the preceding year in the uninfected herd (p <0.01 in both cases). This difference 
of response could be due to the presence of some Coxiella burnetii in the environment and then bacterium spread 
between cows within the infected herds which boosted the immunity of the vaccinated cattle contrarily to the 
animals located in the non infected herds were no antigenic stimulation was provided. 
To determine a putative booster effect of the skin-test on the humoral response, the antibody titers before and 
after the skin test (10 days after) were compared. The antibody titers were significantly higher (p < 0.02) 10 days 
88  Rodolakis A et al. / Procedia in Vaccinology 1 (2009) 85–88 
after the skin-test (mean titer 111 + 81) than the day of the skin-test (mean titer 87 + 79) highlighting that the small 
amount of antigen injected for the skin-test was sufficient to boost the production of antibodies. 
The number of animals experiencing a boosted antibody response (65/139), as defined by an index S  0.3, did 
not differ significantly either between skin-tested positive or negative animal, or between seropositive or 
seronegative animals (Table 2). The number of vaccination and the age at the time of vaccination did not 
significantly affect the number of animals presenting a booster effect. However there were significantly less heifers 
presenting a booster effect in the uninfected herd than in the infected herds (p < 0.05). 
Table 2. Distribution of animals experiencing or not a booster effect according to their skin-test and serological statuses and their 
lactation number 
Infected herds Uninfected herd Skin test ELISA Heifers Cows Booster 
effect 
Neg Posa Negb Posb Vac1c Vac2c Vac1c Vac2cd Heifers Cows 
Yes 23 40 30 33 21 3 13 9 6 11 
No 28 50 32 46 16 2 10 23 16 11 
a) Pos = the skin test positive was considered positive when a nodular area > 1cm was observed. 
b) Neg = ELISA negative S/P ratio < 40; Pos S/P ratio > 40 
c) VAC1 = animals vaccinated for the first time 1 year before (i.e. 1 time), VAC2 = animals vaccinated the 2 preceding years  
d) one blood sample was missing, excluding one cow for study of the booster effect. 
The use of skin-test followed by the detection of subsequent antibody response was supposed to be a relevant 
method to assess the presence of a post-vaccination immunity [6] because it could be a sign of the ability of the 
animals to react to the contact of virulent Coxiella burnetii. The present results seemed indicate that the heifers from 
the uninfected herd were less protected (in terms of duration of protection) than the animals located in infected herds 
included in this study. Indeed one year after vaccination, 84 % (119/142) of the animals still exhibited a humoral 
and/or cellular immune response or a booster effect. But among the 24 animals without any immune response 17 
(70.8%) were from the uninfected herd and 15 of which were heifers. Sixty eight percent of the heifers in the 
uninfected herd were skin-tested negative and ELISA-tested negative and did not become ELISA positive after the 
skin test. In contrast, only 5/42 (11.9 %) heifers and 2/56 (3.6 %) of the cows located in infected herds and 3/22 
(11.6 %) of the cows of uninfected were detected negative in every test. 
4. Conclusion 
This study suggested that while a very low proportion of cows vaccinated one time in infected herds need a 
booster during the second year, this annual booster seemed very relevant for heifers especially in uninfected herds. 
The skin test performed at least 3 days before vaccination could be a useful tool to detect the animals with a 
sufficient cellular immunity and then to optimize the selection of target animals to revaccinate. In routine practice, 
due to the quite systematic susceptible status of heifers, the vaccination could be implemented as soon as possible 
(at 3-4 months of age for example) with an annual booster before the first artificial insemination, leading to both an 
expected maximum booster effect (present study results) and a prevention effect of C. burnetii shedding [4]. 
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